Novo Nordisk (NVO) stock rises after partnering with Amazon Pharmacy to offer FDA-approved weight-loss pill, oral Wegovy, at competitive prices. The deal opens up a massive distribution channel, boosting market penetration opportunities. NVO shares are currently trading at a discount with significant growth potential expected in the obesity treatment market. Wall Street remains optimistic about NVO stock, with a consensus rating of “Moderate Buy” and price targets indicating an 18% potential upside. Analysts believe the oral Wegovy launch could drive margin expansion and market share growth in the coming years.

Read more at Barchart: Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?